VNDA Stock Analysis: Buy, Sell, or Hold?
VNDA - Vanda Pharmaceuticals Inc.
$5.90
-0.05 (-0.84%)
▼
5d:
+2.97%
30d:
-4.68%
90d:
-13.49%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When VNDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: VNDA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: VNDA shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: VNDA is currently trading at $5.90, which is considered slightly low relative to its 30-day fair value range of $5.89 to $6.31.
Technical Outlook: Technically, VNDA is in a downtrend. Immediate support is located at $5.61, while resistance sits at $6.28.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.12 (+139.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VNDA is in a downtrend. Immediate support is located at $5.61, while resistance sits at $6.28.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $14.12 (+139.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.89 -
$6.31
Company Quality Score
56/100
(HOLD)
Options IV Signal
1th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 1th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 139.4% below Wall St target ($14.12)
Trading Range Analysis
30-Day Trading Range
$5.89 -
$6.31
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.72
(12.3%)
Support & Resistance Levels
Support Level
$5.61
Resistance Level
$6.28
Current Trend
Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.66
Wall Street Target
$14.13
(+139.4%)
Revenue Growth (YoY)
3.4%
Earnings Growth (YoY)
-95.9%
Profit Margin
-110.0%
Share & Embed Analysis
Last updated: June 24, 2026 9:08 PM ET
Data refreshes hourly during market hours. Next update: 10:08 PM
Data refreshes hourly during market hours. Next update: 10:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VNDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Gunther Birznieks
SELL
42431 shares
2026-03-02
Joakim Wijkstrom
SELL
30800 shares
2026-03-02
Kevin Patrick Moran
SELL
42442 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 60 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 59 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
